These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 9265351)
1. [Criteria for assessing the efficacy of brachytherapy of uveal melanomas, complications of therapy and there prevention]. Brovkina AF; Zarubeí GD; Val'skií VV Vestn Oftalmol; 1997; 113(3):14-6. PubMed ID: 9265351 [TBL] [Abstract][Full Text] [Related]
2. Ocular complications after iodine brachytherapy for large uveal melanomas. Puusaari I; Heikkonen J; Kivelä T Ophthalmology; 2004 Sep; 111(9):1768-77. PubMed ID: 15350335 [TBL] [Abstract][Full Text] [Related]
4. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Puusaari I; Heikkonen J; Kivelä T Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045 [TBL] [Abstract][Full Text] [Related]
5. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Toivonen P; Kivelä T Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837 [TBL] [Abstract][Full Text] [Related]
6. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155 [TBL] [Abstract][Full Text] [Related]
7. 18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma. van Ginderdeuren R; van Limbergen E; Spileers W Br J Ophthalmol; 2005 Oct; 89(10):1306-10. PubMed ID: 16170122 [TBL] [Abstract][Full Text] [Related]
8. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063 [TBL] [Abstract][Full Text] [Related]
9. Ruthenium plaque radiation therapy for iris and iridociliary melanomas. Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343 [TBL] [Abstract][Full Text] [Related]
11. [Validation of the use of brachytherapy in uveal melanomas of juxtapapillary localization]. Brovkina AF; Zarubeĭ GD; Fishkin IuG Vestn Oftalmol; 1991; 107(6):41-4. PubMed ID: 1781123 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of malignant melanomas of the uvea with 106-ruthenium applicators. Report on the first 100 Essen cases]. Foerster MH; Bornfeld N; Wessing A; Schulz U; Schmitt G; Meyer-Schwickerath G Klin Monbl Augenheilkd; 1984 Dec; 185(6):490-4. PubMed ID: 6527503 [TBL] [Abstract][Full Text] [Related]
17. Possible effects of radiobiological parameters on metastatic spread of uveal melanomas treated with 106Ru plaques. Kleineidam M; Guthoff R Ger J Ophthalmol; 1994 Jan; 3(1):22-5; discussion 25-6. PubMed ID: 8142877 [TBL] [Abstract][Full Text] [Related]
18. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy. Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528 [TBL] [Abstract][Full Text] [Related]
19. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)]. Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984 [TBL] [Abstract][Full Text] [Related]
20. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Schilling H; Sehu KW; Lee WR Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):2081-92. PubMed ID: 9331272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]